A Multi-center, Double-blind, Randomized, Active Reference, Parallel Group Study to Evaluate the Efficacy, Safety and Tolerability of a 10-day Twice Daily Oral Administration of Three Doses of Cadazolid (ACT-179811) in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)

Trial Profile

A Multi-center, Double-blind, Randomized, Active Reference, Parallel Group Study to Evaluate the Efficacy, Safety and Tolerability of a 10-day Twice Daily Oral Administration of Three Doses of Cadazolid (ACT-179811) in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Cadazolid (Primary) ; Vancomycin
  • Indications Clostridium infections; Diarrhoea
  • Focus Therapeutic Use
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 03 Oct 2015 Results published in the Journal of Antimicrobial Chemotherapy.
    • 10 Sep 2013 Results presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy.
    • 10 Sep 2013 Data presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013), according to an Actelion media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top